Cargando…
The role of bone‐modifying agents in myeloma bone disease
Bone disease is common in patients with multiple myeloma (MM), which manifests as bone pain and skeletal‐related events (SREs) such as pathological fractures and spinal cord compression. Myeloma bone disease (MBD) can adversely affect the quality of life of patients and have negative effects on morb...
Autores principales: | Lu, Huifang, Pundole, Xerxes, Lee, Hans C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328802/ https://www.ncbi.nlm.nih.gov/pubmed/34368608 http://dx.doi.org/10.1002/jbm4.10518 |
Ejemplares similares
-
Autoimmune Myelofibrosis and Systemic Lupus Erythematosus in a Middle-Aged Male Presenting Only with Severe Anemia: A case report
por: Pundole, Xerxes, et al.
Publicado: (2015) -
New agents in the Treatment of Myeloma Bone Disease
por: Ring, Elizabeth S., et al.
Publicado: (2017) -
Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018) -
Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
por: Teramachi, Jumpei, et al.
Publicado: (2023) -
Use of bone‐modifying agents and clinical outcomes in older adults with multiple myeloma
por: Olszewski, Adam J., et al.
Publicado: (2019)